Dosiou Chrysoula, Kossler Andrea Lora
Division of Endocrinology, Stanford University School of Medicine, Stanford, California 94305, USA.
Department of Ophthalmology, Stanford University School of Medicine, Stanford, California 94305, USA.
J Endocr Soc. 2021 Mar 17;5(5):bvab034. doi: 10.1210/jendso/bvab034. eCollection 2021 May 1.
Thyroid eye disease (TED) is a complex inflammatory disease that can have a long clinical course with sight-threatening and debilitating ocular sequelae. Until recently, there were limited therapeutic options available. In the last decade we have gained a deeper understanding of the underlying pathophysiology, which has led to the development of novel effective targeted therapies. This article discusses the challenges encountered in the clinical evaluation and treatment of TED patients, with the goal to empower endocrinologists and ophthalmologists to work together to provide effective multidisciplinary care. We will review recommendations of past clinical guidelines around evaluation and management of TED patients, discuss the randomized controlled trials of new biologic therapies, and explore how to navigate the emerging therapeutic landscape.
甲状腺眼病(TED)是一种复杂的炎症性疾病,临床病程可能较长,并伴有威胁视力和导致功能障碍的眼部后遗症。直到最近,可用的治疗选择仍然有限。在过去十年中,我们对其潜在的病理生理学有了更深入的了解,这促成了新型有效靶向治疗方法的开发。本文讨论了甲状腺眼病患者临床评估和治疗中遇到的挑战,目的是使内分泌科医生和眼科医生能够共同努力,提供有效的多学科护理。我们将回顾过去关于甲状腺眼病患者评估和管理的临床指南建议,讨论新生物疗法的随机对照试验,并探索如何应对新兴的治疗格局。